Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2

Molecular Cell

Volumn 11, Issue 1, 2003, Pages 113-126

  Mukhopadhyay, Debnath ^a   Houchen, Courtney W ^a,b   Kennedy, Susan ^a   Dieckgraefe, Brian K ^a,b   Anant, Shrikant ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CYCLOOXYGENASE 2; LUCIFERASE; MESSENGER RNA; NUCLEAR PROTEIN; PROSTAGLANDIN; PROTEIN CUGBP2; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOCYTOPLASMIC TRANSPORT; NUCLEOTIDE SEQUENCE; PROTEIN RNA BINDING; PROTEIN TRANSPORT; RADIATION; RADIATION PROTECTION; RNA SEQUENCE; RNA STABILITY; TRANSLATION REGULATION;

EID: 0037245474     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00012-1     Document Type: Article

References (43)

1. Anant S., Davidson N.O. An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1. binding of Apobec-1 to this motif in the 3′ untranslated region of c-myc increases mRNA stability Mol. Cell. Biol. 20:2000;1982-1992.
2. Anant S., Henderson J.O., Mukhopadhyay D., Navaratnam N., Kennedy S., Min J., Davidson N.O. Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor J. Biol. Chem. 276:2001;47338-47351.
3. Anant S., Mukhopadhyay D., Hirano K.I., Brasitus T.A., Davidson N.O. Apobec-1 transcription in rat colon cancer. decreased apobec-1 protein production through alterations in polysome distribution and mRNA translation associated with upstream AUGs Biochim. Biophys. Acta. 1575:2002;54-62.
4. Caskey C.T., Swanson M.S., Timchenko L.T. Myotonic dystrophy. discussion of molecular mechanism Cold Spring Harb. Symp. Quant. Biol. 61:1996;607-614.
5. Charlet B.N., Logan P., Singh G., Cooper T.A. Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing. Mol. Cell. 9:2002;649-658.
6. Chlebowski R.T. Breast cancer risk reduction. strategies for women at increased risk Annu. Rev. Med. 53:2002;519-540.
7. Choi D.K., Ito T., Mitsui Y., Sakaki Y. Fluorescent differential display analysis of gene expression in apoptotic neuroblastoma cells. Gene. 223:1998;21-31.
8. Cok S.J., Morrison A.R. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J. Biol. Chem. 276:2001;23179-23185.
9. Dannenberg A.J., Altorki N.K., Boyle J.O., Lin D.T., Subbaramaiah K. Inhibition of cyclooxygenase-2. an approach to preventing cancer of the upper aerodigestive tract Ann. NY Acad. Sci. 952:2001;109-115.
10. Dixon D.A., Kaplan C.D., McIntyre T.M., Zimmerman G.A., Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J. Biol. Chem. 275:2000;11750-11757.
11. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., Prescott S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108:2001;1657-1665.
12. Fan X.C., Steitz J.A. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17:1998;3448-3460.
13. Gallouzi I.E., Brennan C.M., Stenberg M.G., Swanson M.S., Eversole A., Maizels N., Steitz J.A. HuR binding to cytoplasmic mRNA is perturbed by heat shock. Proc. Natl. Acad. Sci. USA. 97:2000;3073-3078.
14. Gamliel A., Teicher C., Michaelson D.M., Pradier L., Hartmann T., Beyreuther K., Stein R. Increased expression of presenilin 2 inhibits protein synthesis. Mol. Cell. Neurosci. 19:2002;111-124.
15. Good P.J., Chen Q., Warner S.J., Herring D.C. A family of human RNA-binding proteins related to the Drosophila Bruno translational regulator. J. Biol. Chem. 275:2000;28583-28592.
16. Gou Q., Liu C.H., Ben-Av P., Hla T. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3′-untranslated region. Biochem. Biophys. Res. Commun. 242:1998;508-512.
17. Grosset C., Chen C.Y., Xu N., Sonenberg N., Jacquemin-Sablon H., Shyu A.B. A mechanism for translationally coupled mRNA turnover. interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex Cell. 103:2000;29-40.
18. Hanson W.R., Thomas C. 16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat. Res. 96:1983;393-398.
19. Hsi L.C., Baek S.J., Eling T.E. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp. Cell Res. 256:2000;563-570.
20. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256:2000;42-49.
21. Kedersha N.L., Gupta M., Li W., Miller I., Anderson P. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J. Cell Biol. 147:1999;1431-1442.
22. Ladd A.N., Charlet N., Cooper T.A. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol. Cell. Biol. 21:2001;1285-1296.
23. Ma W.J., Chung S., Furneaux H. The Elav-like proteins bind to AU-rich elements and to the poly(A) tail of mRNA. Nucleic Acids Res. 25:1997;3564-3569.
24. Macdonald P. Diversity in translational regulation. Curr. Opin. Cell Biol. 13:2001;326-331.
25. Mankodi A., Logigian E., Callahan L., McClain C., White R., Henderson D., Krym M., Thornton C.A. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 289:2000;1769-1773.
26. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol. 11:2001;290-299.
27. Niranjanakumari S., Lasda E., Brazas R., Garcia-Blanco M.A. Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods. 26:2002;182-190.
28. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
29. Peng S.S., Chen C.Y., Xu N., Shyu A.B. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J. 17:1998;3461-3470.
30. Philips A.V., Timchenko L.T., Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 280:1998;737-741.
31. Piecyk M., Wax S., Beck A.R., Kedersha N., Gupta M., Maritim B., Chen S., Gueydan C., Kruys V., Streuli M., Anderson P. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 19:2000;4154-4163.
32. Prescott S.M., Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta. 1470:2000;M69-M78.
33. Pyo H., Choy H., Amorino G.P., Kim J.S., Cao Q., Hercules S.K., DuBois R.N. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 7:2001;2998-3005.
34. Riehl T., Cohn S., Tessner T., Schloemann S., Stenson W.F. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology. 118:2000;1106-1116.
35. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 58:1998;5354-5360.
36. Roberts R., Timchenko N.A., Miller J.W., Reddy S., Caskey C.T., Swanson M.S., Timchenko L.T. Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. Proc. Natl. Acad. Sci. USA. 94:1997;13221-13226.
37. Shao J., Sheng H., Inoue H., Morrow J.D., DuBois R.N. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275:2000;33951-33956.
38. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 90:1998;1609-1620.
39. Timchenko L.T., Miller J.W., Timchenko N.A., DeVore D.R., Datar K.V., Lin L., Roberts R., Caskey C.T., Swanson M.S. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 24:1996;4407-4414. a.
40. Timchenko L.T., Timchenko N.A., Caskey C.T., Roberts R. Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats. implications for myotonic dystrophy Hum. Mol. Genet. 5:1996;115-121. b.
41. Timchenko N.A., Welm A.L., Lu X., Timchenko L.T. CUG repeat binding protein (CUGBP1) interacts with the 5′ region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms. Nucleic Acids Res. 27:1999;4517-4525.
42. Timchenko N.A., Cai Z.J., Welm A.L., Reddy S., Ashizawa T., Timchenko L.T. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J. Biol. Chem. 276:2001;7820-7826.
43. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:1999;7908-7916.